TPTianjiao Pei

Tianjiao Pei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tianjiao Pei has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Jiayu Liang

    Department of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China

    1 shared publication
  • Junjie Zhao

    Department of Urology, Institute of Urology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China

    1 shared publication
  • Yang Yang

    Department of Urology, Institute of Urology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China

    1 shared publication
  • Yu Shen

    Department of Urology, Institute of Urology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China

    1 shared publication
  • Yuyang Xia

    Department of Urology, Institute of Urology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China

    1 shared publication
  • Zilin Wang

    Department of Urology, Institute of Urology, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China

    1 shared publication

Latest Publications

  • Open Access

    Long noncoding RNA H19: functions and mechanisms in regulating programmed cell death in cancer

    by Yuyang Xia, Tianjiao Pei, Junjie Zhao, Zilin Wang, Yu Shen, Yang Yang, Jiayu Liang

    Long noncoding RNAs (lncRNAs) are a group of noncoding RNAs with transcript lengths of >200 nucleotides. Mounting evidence suggests that lncRNAs are closely associated with tumorigenesis. LncRNA H19 (H19) was the first lncRNA to function as an oncogene in many malignant tumors. Apart from the established role of H19 in promoting cell growth, proliferation, invasion, migration, epithelial-mesenchymal transition (EMT), and metastasis, it has been recently discovered that H19 also inhibits programmed cell death (PCD) of cancer cells. In this review, we summarize the mechanisms by which H19 regulates PCD in cancer cells through various signaling pathways, molecular mechanisms, and epigenetic modifications. H19 regulates PCD through the Wnt/β-catenin pathway and the PI3K–Akt–mTOR pathway. It also acts as a competitive endogenous RNA (ceRNA) in PCD regulation. The interaction between H19 and RNA-binding proteins (RBP) regulates apoptosis in cancer. Moreover, epigenetic modifications, including DNA and RNA methylation and histone modifications, are also involved in H19-associated PCD regulation. In conclusion, we summarize the role of H19 signaling via PCD in cancer chemoresistance, highlighting the promising research significance of H19 as a therapeutic target. We hope that our study will contribute to a broader understanding of H19 in cancer development and treatment.